Flags

Earnings warning

Rigel Pharmaceuticals

NSQ:RIGL · US7665597024

BiotechnologySmall

360

Medium confidence — indicative

Value68

Profit price—

Cash yield51

Owner Earnings Yield100

Dividend Yield1

Sales & asset price75

Price/Sales73

EV / Gross Profit90

Price/Book62

Quality66

Returns on capital96

Return on Capital92

Return on Equity100

Profit margins84

EBIT Margin85

Gross Profitability83

Cash truth not applicable for financial companies.

Growth42

Sales growth19

Profit growth81

Reinvestment8

Price momentum57

Safety—

Debt load73

Debt serviceability82

Liquidity100

Sentiment40

Analyst ratings29

Expectations trend33

Opinion Changes50

Price Target Upside15

Market mood47

Value Creation17/20strong value creator

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Rigel Pharmaceuticals generates returns well above its cost of capital, the foundation of durable shareholder value.

Based on 3/5 components.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGS

Founded1996

Employees213

Websiterigel.com

ISINUS7665597024

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

HematologyImmunologyInflammationOncologyCentral Nervous SystemBiotechnologyPharmaceuticalTherapeutics

Description

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. TAVALISSE (fostamatinib disodium hexahydrate) is the company’s first FDA-a…

Analysis

Bargain bin

Rigel Pharmaceuticals, Inc. is priced cheaply, and that invites the natural question of why, since the underlying business scores below average.

Valuation data is not available for this company.

Growth is moderate; the safety picture is uncertain. The company scores 17/20 on our value-creation score: strong value creator. Analyst sentiment is cautious.

Flags to be aware of: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Rigel Pharmaceuticals with its peers

Kura Oncology

NSQ:KURA

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Opus Genetics

NAQ:IRD

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Scilex

NAQ:SCLX

CountryUSA

IndustryPharmaceuticals

SizeSmall

Full Stock Analysis →

Myriad Genetics

NSQ:MYGN

CountryUSA

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

KORU Medical Systems

NAQ:KRMD

CountryUSA

IndustryHealth Care Equipment & Supplies

SizeSmall

Full Stock Analysis →

Cardiol Therapeutics

TOR:CRDL

CountryCanada

IndustryPharmaceuticals

SizeX-Small

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →